reliabl
use
rapid
igmigg
antibodi
test
diagnosi
infect
preliminari
report
journal
infect
doi
http
doi
sir
sinc
decemb
novel
coronaviru
emerg
caus
pandem
diseas
known
coronaviru
diseas
februari
th
outbreak
began
itali
present
world
worst
affect
countri
diagnosi
covid
base
molecular
test
aim
detect
viru
rna
respiratori
sampl
nasopharyng
swab
ns
bronchial
aspir
ba
imperfect
gold
standard
give
fals
neg
amount
viral
genoma
insuffici
correct
timewindow
viral
replic
miss
test
igm
igg
product
respons
viral
infect
might
simpl
method
enhanc
detect
sensit
accuraci
molecular
test
addit
may
use
screen
purpos
assess
antibodi
profil
larg
popul
largescal
screen
program
use
antibodi
test
current
evalu
differ
govern
recent
test
rapid
detect
combin
igg
igm
antibodi
human
blood
serumplasma
becom
avail
soon
kit
commerci
avail
assess
reliabl
use
iggigm
antibodi
rapid
patient
suspect
covid
suggest
radiologicalclin
find
neg
molecular
test
asymptomat
control
neg
molecular
test
patient
molecular
test
use
ns
ba
arriv
emerg
room
covid
symptom
rna
sampl
detect
realtim
revers
transcriptas
quantit
pcr
rtpcr
assay
accord
guidelin
qualit
assess
igg
igm
perform
use
rapid
immunochromatograph
assay
hospit
stay
confirm
case
upon
admiss
emerg
room
suspici
case
follow
manufactur
instruct
respons
obtain
within
minut
use
blood
test
allow
detect
singl
antibodi
combin
presenc
absenc
antibodi
express
respect
group
confirm
covid
mean
age
yr
two
patient
intub
sever
diseas
treat
non
invas
ventil
andor
therapi
time
symptom
onset
antibodi
test
rang
day
overal
seroconvers
rate
igm
igg
four
confirm
case
neg
igm
igg
igmigg
among
two
patient
test
day
symptom
onset
sinc
recent
report
show
median
time
igm
igg
detect
symptom
onset
day
respect
reason
two
like
earli
test
exclud
two
remain
patient
median
time
day
symptom
onset
convers
rate
group
suspect
covid
mean
age
yr
yr
old
man
consid
highli
probabl
case
igm
igg
day
symptom
onset
two
neg
molecular
test
base
consist
clinicalradiolog
antibodi
test
find
admit
properli
treat
covid
remain
patient
suspect
covid
two
three
neg
molecular
testi
na
confirm
neg
test
bronchial
aspir
consist
igmigg
healthi
control
igmigg
overal
includ
test
concord
rtpcr
antibodi
test
tabl
cohen
k
substanti
agreement
consid
molecular
test
gold
standard
diagnosi
sensit
specif
antibodi
test
respect
reason
two
patient
confirm
covid
neg
iggigm
time
seroconvers
alreadi
expect
remain
unclear
one
yr
old
woman
immunesenesc
explain
find
howev
patient
young
immunocompet
must
consid
issu
relat
test
perform
eg
lower
limit
detect
correct
time
detect
igm
igg
respons
infect
far
unclear
studi
avail
diverg
result
preliminari
data
suggest
rapid
iggigm
test
reliabl
evidenc
seroconvers
long
test
perform
day
symptom
onset
find
confirm
larger
sampl
test
could
put
mean
assess
popul
immun
group
suspect
covid
anyway
small
found
mainli
consist
neg
molecular
neg
antibodi
test
howev
antibodi
test
perform
earlier
compar
group
confirm
diseas
median
day
vs
day
may
bias
result
test
patient
opinion
antibodi
test
quit
reliabl
use
sinc
advantag
pointofcar
test
give
respons
within
minut
patient
present
discrep
clinicalradiolog
featur
molecular
test
rapid
antibodi
detect
might
addit
element
help
clinician
make
correct
diagnosi
true
long
test
perform
within
first
day
symptom
onset
inde
studi
grant
investig
diagnost
screen
valu
test
